Fig. 2

CCR6+ ILC3s accumulate in the inflamed joints in mice. a (Left) absolute number of ILCs in peripheral blood of control mice (n = 8), pre-arthritic mice (n = 13), and mice with arthritis (n = 11) (Kruskal-Wallis test; p = 0.7605). (Middle) absolute number of ILCs in popliteal lymph nodes of control mice (n = 5), pre-arthritic mice (n = 10), and mice with arthritis (n = 11) (Kruskal-Wallis test; p = 0.1708). (Right) absolute number of ILCs in joints of pre-arthritic mice (n = 5) and mice with arthritis (n = 7). b Comparison of the proportion of each ILC subset among total ILCs in the joints of pre-arthritic (n = 5) and arthritic (n = 7) mice. The proportion of CCR6+ ILC3s in the joints of arthritic mice was greater than that seen in pre-arthritic mice. Data are expressed as a percentage of total ILCs. c The proportion of CCR6+ ILC3s in the peripheral blood, popliteal lymph nodes, and joints of arthritic mice. The proportion of CCR6+ ILC3s increased in the joints compared to peripheral blood or popliteal lymph nodes (Kruskal-Wallis test; p < 0.0001). In all three panels, data points in graphs represent individual mice. Results are expressed as the median and interquartile range based on the Wilcoxon rank-sum test. (*p < 0.05, **p < 0.01, ***p < 0.001). N.S., not significant; N.D., not detected; PB, peripheral blood; PLNs, popliteal lymph nodes